The US Food and Drug Administration (FDA) announced it will give priority review status to Amgen’s application to market ivabradine as a treatment for chronic heart failure.
The drug works to slow the heart rate in appropriate patients without causing negative effects on cardiac rhythms. It was developed by Les Laboratoires Servier in Suresnes, France, and first approved by the European Medicines Agency (EMA) as Procoralan in 2005. According to Servier, a global pharmaceutical firm, Procoralan (also sold as Corlentor) is available in 102 countries.
As the nation tries to cut its health-care costs critics of reform have worried that some patients who need expensive though risky procedures like coronary artery bypass graft surgery (CABG) might not get them.
But a new Harvard School of Public Health study could allay those fears.
Low levels of enrollment and more favorable risk profiles for participants raise questions about whether the findings of clinical trials are generalizable to typical patients with myocardial infarction, according to research published in the Aug. 27 issue of the Journal of the American Medical Association.
For patients with first unprovoked venous thromboembolism, aspirin after anticoagulant treatment reduces the risk of recurrence, according to a study published online Aug. 25 in Circulation.
Self-monitoring with self-titration of antihypertensive medications is associated with lower blood pressure for patients with hypertension at risk for cardiovascular disease, according to a study published in the Aug. 27 issue of the Journal of the American Medical Association.
The nation’s youth, and its smoke-free air need federal protection from vapors from e-cigarettes, according to a set of recommendations released Aug. 25 by the American and Heart Association.
Cognitive impairment is associated with an increased risk of subsequent stroke, according to a meta-analysis published online Aug. 25 in CMAJ, the journal of the Canadian Medical Association.